rivatas 15

Indications

• Constipation
• Faecal impaction

Dosage

Children: For children aged 1 month to 5 years, the recommended dosage is 2.5 to 5 mL twice daily. Dosage may vary based on individual response and should be guided by a healthcare professional.

Adults: For adults, the typical dosage is 1 to 2 tablespoons (around 15 to 30 mL) mixed with at least 240 mL of water, taken up to three times daily. It is important to ensure adequate fluid intake to avoid gastrointestinal obstruction.

Mechanism of action

Methylcellulose acts as a bulk-forming laxative by absorbing water in the gastrointestinal tract. This increases the stool's bulk and promotes bowel motility through mechanical stimulation of the intestinal walls, which enhances peristalsis. It does not undergo significant metabolism and directly influences the physical properties of the stool.

Pharmacodynamics

The pharmacodynamic profile of methylcellulose indicates that it increases stool bulk and moisture content, facilitating easier passage of stool. The osmotic effect helps to soften the stool, while the bulk created stimulates intestinal contractions, reducing the time stool remains in the colon and alleviating constipation.

Pharmacokinetics

Methylcellulose is not absorbed systemically as it is a non-digestible fiber. Its effects are localized to the gastrointestinal tract. After oral administration, it acts primarily in the intestines, where it retains water to form a gel-like mass. The onset of action may vary, with effects usually observed within 24 to 72 hours.

Adverse effects

• abdominal discomfort
• bloating
• diarrhea
• nausea

Precautions

• Ensure adequate fluid intake to prevent intestinal blockage.
• Use cautiously in patients with pre-existing gastrointestinal disorders.

Pregnancy

Methylcellulose is generally considered safe during pregnancy. However, it is advisable to consult with a healthcare professional before use.

Breast-feeding

Methylcellulose is excreted in breast milk. Consult a healthcare provider for advice on use while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral liquid
• Granules

Indications

• Prophylaxis of venous thromboembolism following knee replacement surgery
• Prophylaxis of venous thromboembolism following hip replacement surgery
• Treatment of deep vein thrombosis
• Treatment of pulmonary embolism

Dosage

Adults: For the prophylaxis of venous thromboembolism following knee replacement surgery: 10 mg once daily for 2 weeks, starting 6–10 hours

Mechanism of action

Rivaroxaban competitively inhibits both free and clot-bound factor Xa. Factor Xa is essential for the conversion of prothrombin to thrombin, which is necessary for fibrinogen to be activated into fibrin, leading to clot formation. By inhibiting factor Xa, rivaroxaban effectively terminates the amplification of thrombin generation, preventing thrombus formation. Its action is irreversible and does not require a cofactor, distinguishing it from other anticoagulants like heparin.

Pharmacodynamics

Rivaroxaban exhibits anticoagulant properties by directly binding to factor Xa. This binding prevents the activation of prothrombin, thereby blocking the coagulation cascade and thrombus formation. Unlike traditional anticoagulants, rivaroxaban does not utilize antithrombin III to exert its effects, and it is administered orally, making it more convenient compared to parenteral anticoagulants.

Pharmacokinetics

Rivaroxaban is rapidly absorbed and reaches peak plasma concentrations within 2-4 hours after oral administration. It is extensively metabolized in the liver, primarily by CYP3A4 and CYP2J2, and is also a substrate for P-glycoprotein. The half-life of rivaroxaban is approximately 5-9 hours in healthy individuals, and it is excreted via both renal and fecal routes, with about 66% excreted as metabolites and 28% as unchanged drug.

Contra-indications

• Active bleeding
• Bacterial endocarditis
• Active gastrointestinal ulcer

Adverse effects

• Anaemia
• Haemorrhage
• Chest pain
• Dyspnoea
• Fever
• Hepatic function abnormality
• Nausea
• Oedema
• Platelet abnormalities
• Thrombocytopenia
• Vomiting
• Wound secretion
• Anxiety
• Confusion
• Constipation
• Cough
• Diarrhoea
• Dizziness
• Drowsiness
• Fatigue
• Gastritis
• Gastrointestinal discomfort
• Genital oedema
• Headache
• Hyperbilirubinaemia
• Hypersensitivity
• Hypokalaemia
• Hypotension
• Leg pain
• Post procedural infection
• Syncope
• Vasodilation
• Vertigo

Interactions

• tucatinib+rivaroxaban: Moderate (increases exposure)
• vemurafenib+rivaroxaban: Moderate (increases exposure)
• antiarrhythmics+rivaroxaban: Unknown (increases exposure)
• antiepileptics (carbamazepine, phenobarbital, phenytoin, primidone)+rivaroxaban: Unknown (decreases exposure)
• ciclosporin+rivaroxaban: Unknown (increases exposure)
• mitotane+rivaroxaban: Unknown (decreases exposure)
• NNRTIs+rivaroxaban: Unknown (decreases exposure)
• St. John's Wort+rivaroxaban: Unknown (decreases exposure)

Precautions

• Elderly patients
• Low body weight
• Spinal or epidural anaesthesia (risk of spinal haematoma)
• Patients with a history of bleeding disorders
• Patients undergoing percutaneous coronary intervention
• Patients with renal impairment

Pregnancy

Manufacturer advises to avoid unless potential benefit outweighs possible risk-no information available.

Breast-feeding

Present in milk in animal

Indications

• Constipation
• Dietary fiber supplementation
• Irritable bowel syndrome
• Diverticular disease
• Weight management

Dosage

Children: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Adults: Refer to appropriate guidelines for specific dosage; generally taken with adequate fluid intake.

Mechanism of action

Cellulose acts primarily as a bulk-forming laxative. It absorbs water in the intestines, which increases stool bulk and stimulates peristalsis, thus facilitating bowel movements. Additionally, cellulose is not digestible by human enzymes, leading to fermentation by gut bacteria, which may enhance gut health and alter gut microbiota composition.

Pharmacodynamics

Cellulose increases stool weight and frequency of bowel movements. It works by retaining water in the intestines, leading to softer stools and improved passage through the gastrointestinal tract. The bulking effect of cellulose can help alleviate constipation and promote overall digestive health. It may also play a role in cholesterol reduction and glycemic control through its effects on digestion and absorption of nutrients.

Pharmacokinetics

Cellulose is not absorbed into the bloodstream due to its indigestible nature. Instead, it passes through the gastrointestinal tract, where it adds bulk to the stool. Its fermentation by colonic bacteria produces short-chain fatty acids, which may have beneficial effects on colon health. The onset of action for cellulose as a laxative can vary but is generally within 24 to 72 hours after ingestion.

Adverse effects

• Bloating
• Flatulence
• Diarrhea
• Abdominal discomfort

Precautions

• Use with caution in patients with a history of gastrointestinal disorders.
• Monitor for potential allergic reactions in sensitive individuals.

Pregnancy

Cellulose is generally considered safe during pregnancy as it is a non-toxic, indigestible fiber.

Breast-feeding

Cellulose is also considered safe during breastfeeding; it is excreted in breast milk in negligible amounts.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Capsules
• Tablets
• Granules

Indications

• Protection of active ingredients in pharmaceutical formulations
• Enhancement of drug stability
• Improvement of palatability in oral dosage forms
• Facilitation of swallowing for patients with difficulty
• Controlled release of active substances

Dosage

Children: Refer to specific product information for pediatric dosing recommendations, as this varies widely based on the formulation and active ingredient.

Adults: Refer to specific product information for dosing instructions, as this varies based on the formulation and active ingredient.

Mechanism of action

The mechanism of action for coated formulations generally involves the creation of a barrier that protects the active pharmaceutical ingredient from environmental factors like moisture and oxygen. In some cases, the coating may also control the release of the drug, allowing for extended or modified release profiles that enhance therapeutic effects. Specific coatings might interact with the gastrointestinal environment, affecting solubility and absorption rates.

Pharmacodynamics

Pharmacodynamics of coated formulations can vary widely depending on the active ingredient and the nature of the coating itself. Coatings may be designed to dissolve at specific pH levels, ensuring that the drug is released in the optimal environment for absorption. The protective nature of the coat can also affect the bioavailability of the active compound, influencing its efficacy and safety profile.

Pharmacokinetics

Pharmacokinetics of coated drugs involve considerations of absorption, distribution, metabolism, and excretion. The coating can alter the rate of drug absorption, with some coatings designed to delay release until the drug reaches the intestines. The distribution of the drug throughout the body may also be affected by the coating, as it can influence the solubility and stability of the drug in systemic circulation. Metabolism and excretion can be influenced by the characteristics of the coating material and the nature of the active ingredient.

Pregnancy

Consult healthcare provider before use. Limited data available on safety.

Breast-feeding

Consult healthcare provider before use. Limited data available on safety.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Hypovolemic shock
• Severe burns
• Postoperative fluid replacement
• Sepsis
• Trauma management

Dosage

Children: Refer to established guidelines for specific dosing, as it varies based on the type of colloidal solution used and the clinical condition being treated.

Adults: Refer to established guidelines for specific dosing, as it varies based on the type of colloidal solution used and the clinical condition being treated.

Mechanism of action

Colloidal solutions work by maintaining oncotic pressure in the blood, thus helping to retain fluid within the vascular system. This is primarily due to the large molecular weight of the colloidal particles, which cannot easily pass through capillary walls. The presence of colloids in the blood helps to draw water into the circulation, increasing blood volume and improving tissue perfusion.

Pharmacodynamics

The pharmacodynamics of colloidal solutions are centered on their ability to exert osmotic pressure, which helps maintain blood volume and pressure. This effect is particularly important in conditions such as hypovolemia and shock, where fluid replacement is necessary to restore hemodynamic stability. The efficacy of colloidal solutions can vary depending on the type of colloid used, as well as the underlying clinical condition being treated.

Pharmacokinetics

Colloidal solutions are typically administered intravenously and their pharmacokinetics can vary based on the specific formulation. Generally, colloids are distributed throughout the vascular compartment and have a longer duration of action compared to crystalloids, as they remain in circulation longer. The elimination of colloids is primarily through the reticuloendothelial system, where they are metabolized or eliminated by the liver and spleen. Factors such as particle size and composition can influence their distribution and clearance.

Adverse effects

• Allergic reactions
• Injection site reactions
• Nausea
• Vomiting
• Headache
• Fever

Precautions

• Use with caution in patients with known allergies to any component of the formulation
• Monitor for signs of hypersensitivity during administration
• Consider volume overload in patients with cardiac or renal impairment

Pregnancy

The safety of colloidal solutions during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether colloidal solutions are excreted in human milk. Caution should be exercised when administering to breastfeeding mothers.

Storage

Store at room temperature, protect from light, and do not freeze. Keep out of reach of children.

Formulations

• Colloidal silver
• Colloidal gold
• Colloidal iron
• Other metal colloids

Indications

• Used as a disintegrant in tablet formulations
• Enhances the bioavailability of active pharmaceutical ingredients

Dosage

Children: Refer to the specific formulation guidelines, as dosage will vary based on the active ingredient and formulation type.

Adults: Refer to the specific formulation guidelines, as dosage will vary based on the active ingredient and formulation type.

Mechanism of action

Croscarmellose sodium works by swelling and absorbing water when it comes into contact with gastrointestinal fluids. This swelling leads to the rapid disintegration of the tablet or capsule matrix, facilitating the release and absorption of the active pharmaceutical ingredients.

Pharmacodynamics

Croscarmellose sodium is classified as a superdisintegrant. Its ability to rapidly disintegrate solid dosage forms can significantly enhance the dissolution rate of the active ingredient, which is crucial for achieving therapeutic effects in a timely manner.

Pharmacokinetics

Croscarmellose sodium is not absorbed in the gastrointestinal tract and does not exert pharmacological effects in the body. It is considered non-toxic and is excreted unchanged. Its main role is as an excipient, influencing the formulation's characteristics rather than the pharmacokinetics of the active ingredients.

Precautions

• Use with caution in patients with known hypersensitivity to croscarmellose or its components.

Pregnancy

Safety in pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Caution is advised when using during breastfeeding, as safety has not been established.

Storage

Store in a cool, dry place, away from moisture and heat.

Formulations

• Powder
• Granules

Indications

• Used as an excipient in pharmaceutical formulations
• Improves solubility and stability of active ingredients
• Facilitates drug absorption

Dosage

Children: Refer to specific product guidelines as hydroxypropyl is typically used as an excipient and not dosed independently.

Adults: Refer to specific product guidelines as hydroxypropyl is typically used as an excipient and not dosed independently.

Mechanism of action

Hydroxypropyl functions primarily as a solubilizing agent, which aids in the dissolution of poorly soluble drugs. It interacts with water and other solvents to improve the dispersion of pharmaceutical compounds, thereby enhancing their bioavailability. Hydroxypropyl may also facilitate the permeability of drug molecules through biological membranes, contributing to their overall efficacy.

Pharmacodynamics

The pharmacodynamics of hydroxypropyl relate to its role in improving the physicochemical properties of drug formulations. By increasing solubility and stability, hydroxypropyl can enhance the absorption of drugs administered via various routes, including oral and topical. Its non-toxic nature allows for safe incorporation into formulations, making it suitable for a wide range of applications.

Pharmacokinetics

The pharmacokinetics of hydroxypropyl have not been extensively studied as it primarily acts as an excipient rather than an active pharmaceutical ingredient. When used in formulations, it is typically not absorbed into systemic circulation in significant amounts, thereby minimizing potential systemic effects. Hydroxypropyl is generally regarded as safe when used in appropriate amounts in drug formulations.

Pregnancy

Hydroxypropyl is not classified for use during pregnancy, and its safety has not been established. Caution is advised.

Breast-feeding

There is limited information on the excretion of hydroxypropyl in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Indications

• Lactose intolerance
• As a filler or excipient in pharmaceutical formulations

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and clinical context.

Adults: Refer to the BNF for specific dosing information based on clinical context.

Mechanism of action

Lactose is metabolized in the intestine by the enzyme lactase into its constituent monosaccharides, glucose and galactose. In individuals with lactase deficiency, unabsorbed lactose passes into the colon, where it is fermented by bacteria, leading to gas production and osmotic effects that contribute to diarrhea.

Pharmacodynamics

The pharmacodynamics of lactose are primarily related to its effects on gastrointestinal function. In healthy individuals, lactose is effectively broken down into glucose and galactose, which are absorbed and utilized for energy. In individuals with lactose intolerance, the unabsorbed lactose can cause osmotic diarrhea and colonic fermentation, leading to discomfort and symptoms associated with lactose intolerance.

Pharmacokinetics

Lactose is not absorbed in the gastrointestinal tract until it is hydrolyzed into glucose and galactose by lactase. The absorption of glucose and galactose occurs in the small intestine. The half-life is not applicable as lactose is not typically administered as a medication but is rather ingested as a natural component of food. Its metabolism primarily occurs in the intestine.

Adverse effects

• Bloating
• Diarrhea
• Abdominal pain
• Flatulence

Precautions

• Use with caution in patients with lactose intolerance.
• Consider potential for gastrointestinal upset in sensitive individuals.

Pregnancy

Lactose is generally considered safe for use during pregnancy. However, consult a healthcare professional for individual advice.

Breast-feeding

Lactose is safe to use while breastfeeding, as it is a natural sugar present in breast milk.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Powder
• Granules
• Tablets
• Syrup

Indications

• Cleansing agent in topical formulations
• Emulsifying agent in cosmetic products
• Foaming agent in shampoos and body washes

Dosage

Children: Refer to specific product formulations for appropriate concentrations and application methods.

Adults: Refer to specific product formulations for appropriate concentrations and application methods.

Mechanism of action

Lauryl sulfate functions as an anionic surfactant. It reduces the surface tension between different substances, allowing for better spreading and wetting. In the context of cleansing, it facilitates the removal of dirt and oils from the skin and hair by emulsifying these substances, thus making them easier to rinse away with water.

Pharmacodynamics

As a surfactant, lauryl sulfate displays properties that can disrupt cellular membranes and alter permeability. This mechanism is beneficial in enhancing the penetration of other therapeutic agents in topical formulations. However, its irritant potential on skin and mucous membranes should be noted, as it can lead to dryness and irritation with prolonged exposure.

Pharmacokinetics

Lauryl sulfate is primarily applied topically and is not intended for systemic absorption. When used in formulations, it acts locally at the site of application. Its absorption through the skin is minimal, and any systemic exposure is limited. Metabolism and excretion pathways are not well-defined for topical applications, as it is largely washed away after use.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Unknown whether lauryl is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Hypomagnesemia
• Magnesium deficiency
• Cardiac arrhythmias
• Eclampsia
• Asthma exacerbations
• Migraine prophylaxis

Dosage

Children: Refer to the BNF for Children for pediatric dosing recommendations.

Adults: Refer to clinical guidelines or specific product information for adult dosing.

Mechanism of action

Magnesium acts as a cofactor for over 300 enzymatic reactions in the body. It is essential for ATP production, the synthesis of nucleic acids, and the regulation of calcium homeostasis. By modulating calcium channels and neurotransmitter release, magnesium influences neuromuscular transmission and muscle contraction. It also plays a role in stabilizing cellular membranes and protecting against oxidative stress.

Pharmacodynamics

Magnesium's pharmacodynamics involve its effects on various physiological processes, particularly in the cardiovascular and neuromuscular systems. It helps to maintain normal muscle and nerve function and influences cardiac rhythm. Magnesium is known to inhibit excessive calcium influx into cells, thus contributing to vasodilation and lowering blood pressure. It also has a calming effect on the nervous system, which can help alleviate anxiety and promote relaxation.

Pharmacokinetics

Magnesium is absorbed primarily in the small intestine, with the efficiency of absorption being influenced by dietary factors and the presence of other minerals. The body regulates magnesium levels through renal excretion and intestinal absorption. The half-life of magnesium varies depending on the route of administration, with intravenous administration leading to quicker distribution and elimination. The majority of magnesium is stored in the bones, muscles, and soft tissues, with only a small fraction present in the extracellular fluid.

Contra-indications

• Severe renal impairment
• Myasthenia gravis
• Hypocalcemia
• Hypophosphatemia

Adverse effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal cramping
• Hypotension
• Bradypnea
• Muscle weakness

Interactions

• Antibiotics (e.g., tetracyclines, fluoroquinolones) - may bind and reduce their absorption
• Calcium supplements - may compete for absorption
• Diuretics (especially loop diuretics) - can increase the risk of magnesium deficiency
• ACE inhibitors - may enhance the hypotensive effect
• Neuromuscular blocking agents - may potentiate their effects

Precautions

• Use with caution in patients with renal impairment
• Monitor electrolytes in patients with gastrointestinal losses
• Avoid in patients with heart block
• Caution in elderly patients due to potential for electrolyte imbalance

Pregnancy

Magnesium is generally considered safe during pregnancy and is often recommended for certain conditions, such as preeclampsia.

Breast-feeding

Magnesium is excreted in breast milk but is generally considered safe for use during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Oral solution
• Intravenous injection
• Intramuscular injection

Dosage

Children: Refer to specific drug formulations and their respective dosing guidelines.

Adults: Refer to specific drug formulations and their respective dosing guidelines.

Mechanism of action

The mechanism of action for any specific material will depend on the particular active ingredient or excipient in question. For active pharmaceutical ingredients, mechanisms can range from receptor binding and enzyme inhibition to modulation of ion channels, depending on the therapeutic goal. Excipients may serve various roles such as stabilizers, fillers, or binders, facilitating the delivery of the active drug.

Pharmacodynamics

Pharmacodynamics varies widely among different materials. For active ingredients, it reflects their interaction with biological systems, including dose-response relationships and the time course of therapeutic effects. This may involve receptor activation, signal transduction pathways, or metabolic pathways influencing physiological responses. For excipients, pharmacodynamic effects are usually minimal but can affect the release and absorption profiles of the active ingredient.

Pharmacokinetics

Pharmacokinetics of materials, especially active ingredients, involves the study of absorption, distribution, metabolism, and excretion (ADME). Factors influencing pharmacokinetics include the route of administration, formulation characteristics, and patient-specific variables such as age, weight, and organ function. For excipients, their impact on pharmacokinetics is often related to their role in formulation, such as altering the absorption of the active drug.

Indications

• Used as an excipient in tablet formulations
• Used as a bulking agent in capsule formulations
• Used in food products as a thickener or stabilizer

Dosage

Children: Refer to specific product guidelines as dosage will depend on the formulation and the active ingredients.

Adults: Refer to specific product guidelines as dosage will depend on the formulation and the active ingredients.

Mechanism of action

Microcrystalline cellulose acts as a non-digestible filler that enhances the flow properties of powders during the manufacturing of tablets and capsules. It does not have a direct pharmacological action on the body but ensures that the active ingredients are effectively delivered to the patient.

Pharmacodynamics

As a non-active ingredient, microcrystalline cellulose does not exert pharmacodynamic effects typical of active pharmaceutical ingredients. Its primary role is to provide a stable and consistent matrix for the drug, facilitating the release of the active compound once ingested.

Pharmacokinetics

Microcrystalline cellulose is not absorbed in the gastrointestinal tract; it passes through the digestive system largely unchanged. It adds bulk to the stool, which may aid in promoting regular bowel movements. The substance is excreted in feces, where it contributes to dietary fiber intake.

Pregnancy

Data regarding the use of microcrystalline cellulose during pregnancy is limited. It is advisable to consult with healthcare professionals before use.

Breast-feeding

Microcrystalline cellulose is considered safe during breastfeeding, as it is not absorbed systemically.

Storage

Store in a cool, dry place away from direct sunlight and moisture.

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Indications

• Pain relief
• Inflammation reduction
• Fever reduction
• Bacterial infections

Dosage

Children: Always refer to BNF for Children for appropriate dosing based on age and weight.

Adults: Refer to specific product guidelines for precise dosing information based on the formulation and condition being treated.

Mechanism of action

The mechanism of action for the active ingredients in Ready can vary. For instance, if it includes non-steroidal anti-inflammatory drugs (NSAIDs), these work by inhibiting the cyclooxygenase (COX) enzymes, leading to a decrease in the synthesis of prostaglandins, which are mediators of inflammation and pain. If the formulation includes antibiotics, these can work by targeting bacterial cell wall synthesis, protein synthesis, or other bacterial metabolic processes, leading to bacterial cell death.

Pharmacodynamics

Pharmacodynamics will depend on the specific active ingredients within Ready. Generally, NSAIDs exhibit anti-inflammatory, analgesic, and antipyretic effects through their action on COX enzymes. Antibiotics may demonstrate bactericidal or bacteriostatic effects, depending on their class and mechanism of action. The overall effect is a reduction in symptoms associated with infections, inflammation, or pain.

Pharmacokinetics

The pharmacokinetics of Ready will also vary based on the individual components. Typically, NSAIDs are rapidly absorbed, with peak plasma concentrations occurring within a few hours post-administration. They are metabolized primarily in the liver and excreted via the kidneys. Antibiotics may have various absorption rates depending on their formulation, distribution, metabolism, and excretion characteristics, which influence their efficacy and safety profile.

Pregnancy

Consult healthcare provider for use during pregnancy. The effects on fetal development are not well established.

Breast-feeding

Consult healthcare provider before use. The excretion in breast milk is not well studied.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Silicosis
• Chronic obstructive pulmonary disease (COPD)
• Lung cancer associated with silica exposure

Dosage

Adults: Silica is not administered as a drug, but rather

Mechanism of action

Silica, particularly crystalline forms like quartz and cristobalite, can induce cytotoxicity and morphological transformation in cells. The cytotoxic effects are attributed to the presence of silanol groups and trace iron on the silica surface, which can generate reactive oxygen species. These interactions lead to cellular damage and transformation, suggesting multiple molecular mechanisms underlying silica's biological effects. The activity is sensitive to the silica's surface structure and composition, indicating that the biological response is a phenomenon originating from the silica's surface characteristics.

Pharmacodynamics

Silica's pharmacodynamic effects are largely related to its cytotoxic and transforming properties, particularly in lung tissue. The inhalation of crystalline silica can lead to the activation of inflammatory pathways, oxidative stress, and apoptosis in alveolar macrophages and epithelial cells. This can result in chronic inflammation, fibrosis, and ultimately, diseases such as silicosis and lung cancer. The degree of these effects varies based on the type of silica, its crystalline structure, and the presence of surface modifications.

Pharmacokinetics

The pharmacokinetics of silica is complex as it is not absorbed systemically when inhaled or ingested. Instead, inhaled silica particles can deposit in the alveolar region of the lungs, where they may persist for long periods. The body responds to silica exposure through inflammatory processes, and macrophages attempt to phagocytize silica particles. However, the persistence of these particles can lead to chronic lung conditions. Clearance mechanisms are inefficient, leading to prolonged retention in lung tissue.

Adverse effects

• Cytotoxicity
• Morphological transformation of cells
• Respiratory issues
• Silicosis
• Lung cancer

Precautions

• Use caution in occupational settings with silica dust exposure
• Regular monitoring of lung function in exposed individuals

Pregnancy

There is insufficient data on the effects of silica on pregnancy. It is advised to minimize exposure.

Breast-feeding

Limited data available; caution is advised due to potential respiratory effects.

Storage

Store in a cool, dry place, away from moisture and incompatible materials.

Formulations

• Crystalline silica
• Amorphous silica (diatomaceous earth)
• Silica gel

Mechanism of action

Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible. Rivaroxaban, an oral, direct activated factor X (Xa) inhibitor, is an anticoagulant. Factor Xa plays a central role in the blood coagulation cascade by serving as the convergence point for the intrinsic and extrinsic pathways; inhibition of coagulation factor Xa by rivaroxaban prevents conversion of prothrombin to thrombin and subsequent thrombus formation. Rivaroxaban inhibits both free and prothrombinase-bound factor Xa. Unlike fondaparinux, heparin, and the low molecular weight heparins, rivaroxaban binds directly to the active site of factor Xa without the need for a cofactor (e.g., antithrombin III). Rivaroxaban inhibits factor Xa with more than 100,000-fold greater selectivity than other biologically important serine proteases (e.g., thrombin, trypsin, plasmin, factor VIIa, factor IXa, urokinase, activated protein C). Xarelto is an orally bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa (FXa) via the intrinsic and extrinsic pathways plays a central role in the cascade of blood coagulation.

Pharmacodynamics

Rivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.

Mechanism of action

...Some quartz and cristobalite dusts (crystalline) as well as the diatomaceous earths (amorphous), but not the pyrogenic amorphous silica, were cytotoxic and induced morphological transformation of SHE cells in a concentration-dependent manner. The ranking in cytotoxicity was different from that in transforming potency, suggesting two separate molecular mechanisms for the two effects. The cytotoxic and transforming potencies were different from one dust to another, even among the same structural silicas. The type of crystalline structure (quartz vs cristobalite) and the crystalline vs biogenic amorphous form did not correlate with cytotoxic or transforming potency of silica dusts. Comparison of cellular effects induced by original and surface modified samples revealed that several surface functionalities modulate cytotoxic and transforming potencies. The cytotoxic effects appeared to be related to the distribution and abundance of silanol groups and to the presence of trace amounts of iron on the silica surface. Silica particles with fractured surfaces and/or iron-active sites, able to generate reactive oxygen species, induced SHE cell transformation. The results show that the activity of silica at the cellular level is sensitive to the composition and structure of surface functionalities and confirm that the biological response to silica is a surface originated phenomenon. In vivo exposure of rat lungs to crystalline silica either by intratracheal instillation or by inhalation results in an increase in mRNA levels for inducible nitric oxide synthase (iNOS) in bronchoalveolar lavage cells (BALC), elevated nitric oxide (.NO) production by BALC, and an increase in .NO-dependent chemiluminescence (CL) from alveolar macrophages (AM). Induction of iNOS message occurs in both AM and polymorphonuclear leukocytes (PMN) harvested from silica-exposed lungs but is not significantly elevated in lavaged lung tissue. This review presents characteristics of simple and complicated coal workers' pneumoconiosis (CWP) as well as pathologic indices of acute and chronic silicosis by summarizing results of in vitro, animal, and human investigations. These results support four basic mechanisms in the etiology of CWP and silicosis: a) direct cytotoxicity of coal dust or silica, resulting in lung cell damage, release of lipases and proteases, and eventual lung scarring; b) activation of oxidant production by pulmonary phagocytes, which overwhelms the antioxidant defenses and leads to lipid peroxidation, protein nitrosation, cell injury, and lung scarring; c) activation of mediator release from alveolar macrophages and epithelial cells, which leads to recruitment of polymorphonuclear leukocytes and macrophages, resulting in the production of proinflammatory cytokines and reactive species and in further lung injury and scarring; d) secretion of growth factors from alveolar macrophages and epithelial cells, stimulating fibroblast proliferation and eventual scarring. Results of in vitro and animal studies provide a basis for proposing these mechanisms for the initiation and progression of pneumoconiosis. Data obtained from exposed workers lend support to these mechanisms. /The authors/ reported previously that freshly fractured silica (FFSi) induces activator protein-1 (AP-1) activation through extracellular signal-regulated protein kinases (ERKs) and p38 kinase pathways. In the present study, the biologic activities of FFSi and aged silica (ASi) were compared by measuring their effects on the AP-1 activation and phosphorylation of ERKs and p38 kinase. The roles of reactive oxygen species (ROS) in this silica-induced AP-1 activation were also investigated. FFSi-induced AP-1 activation was four times higher than that of ASi in JB6 cells. FFSi also caused greater phosphorylation of ERKs and p38 kinase than ASi. FFSi generated more ROS than ASi when incubated with the cells as measured by electron spin resonance (ESR). Studies using ROS-sensitive dyes and